EATONTOWN, N.J., July 29 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE - News), a leader in the emerging field of biologic products for regenerative healing, today announced that in a July 24, 2009 letter to the Company, the French regulatory agency, afssaps, rescinded its December 17, 2008 order establishing restrictions on the importation and distribution of tissue products processed from donors procured by TB OsteoCentre Bulgaria EAD (“OCBG”), a subsidiary of Osteotech. During its inspections, afssaps obtained and tested a number of samples of Osteotech’s proprietary Grafton® DBM processed from OCBG donor tissue and found no instances of contamination. As a result of this favorable outcome, Osteotech lifted its self-imposed temporary suspension and will begin distributing tissue grafts processed from OCBG donors to its foreign distributors immediately.
